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If one were to state a focus for Dr.
Peters' work it would be for fluid home-
ostasis. His work on body water, elec-
trolytes, and acid-base balance are certain-
ly the most important and the most endur-
ing of his contributions to biomedical sci-
ence. His contributions to the field of dia-
betes extended across the entire spectrum:
carbohydrate metabolism and diabetes,
lipid metabolism and diabetes, plasma
proteins and diabetes, and perhaps most
importantly, the management of diabetes.
At the heart of Dr. Peters' work was
his ability to make quantitative measure-
ments and his ability to apply them to
experimental evidence and patient care,
which is noteworthy, especially consider-
ing the context in which he worked. His
contributions to science and biomedicine
extended from 1917 to 1955. Thus his
work either pre-dated or was concurrent
with some enormous contributions in the
field of diabetes. First and foremost, he
predated the introduction of insulin. From
an experimental point of view and a
patient care point of view, the treatment of
diabetes without insulin is almost mind-
boggling for those of us in the field today.
In addition, Dr. Peters either predated or
spanned the antibiotic era, and it is
unimaginable to think about managing
diabetics prior to that time. He clearly pre-
dated our ideological distinctions of the
forms of diabetes but already had enor-
mous insight into this important issue, and
he clearly predated the ability to measure
polypeptide hormones in blood and to use
these to characterize the etiologic distinc-
tions. Yet again, he had enormous insight
into what would later evolve as more spe-
cific classifications ofthe disease.
As reported in a paper that was pub-
lished in 1917 in the Journal ofBiological
Chemistry, Dr. Peters injected adrenaline
into two patients and observed their blood
sugar going up and their carbon dioxide
going down [1]. His focus is the mecha-
nismofhyperglycemia, andhe talked about
the issue ofwhether vascular changes intro-
duced by adrenaline or the acidosis or the
loss ofalkali, as he puts it, is in factrelated.
He concluded that this is basically due to
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glycogen breakdown - and this was well
before four Nobel Prizes were awarded for
our understanding ofhow adrenaline raises
the blood glucose concentration.
In 1931, he had already begun to talk
about what would later become etiologic
distinctions in diabetes. He had begun to
discuss issues such as insulin resistance.
He used this terminology in the context of
other endocrinopathies, but he clearly
understood the relationship of this to the
more common forms of diabetes. He
focused on protein and fat metabolism. He
was particularly aware that diabetes was a
starvation state, not in the sense of depri-
vation of nutrients, but in the inability to
use those nutrients. He recognized that
deprivation ofthose nutrients was not use-
ful in the treatment of disease, a perspec-
tive that was not prevalent at the time. He
was particularly concerned about the com-
bustion of ketones and about ketoacidosis
and about the nature of acidosis in dia-
betes. He pointed out that bicarbonate is
seldom necessary when insulin is used. He
described in great detail the relationship of
electrolyte depletion to water balance. He
was particularly concerned about the
metabolism ofketoacids and the necessity
of administering carbohydrate in an
attempt to accelerate their combustion,
decrease the accelerated catabolic state in
fatty acid oxidation, but the difficulty in
doing so without creating a greater osmot-
ic load and a greater fluid loss. He and his
colleagues described in great detail a num-
ber of case reports of individual patients,
and he appreciated the enormous hetero-
geneity that was present in each individual
and each case ofdiabetic ketoacidosis. He
also appreciated the fact that these people
needed to be treated as individuals.
Every house officer at Yale knew
about his attempt to use fructose-contain-
ing solutions in the treatment of diabetic
ketoacidosis in an attempt to administer
carbohydrate without increasing the
osmotic load. It was something of a con-
troversial concept as to whether or not this
was possible. Years later, an article pub-
lished in theJune 1999 issue ofDiabetes is
titled "Small amounts offructose marked-
ly augment hepatic glucose uptake in the
conscious dog" [2]. While Dr. Peters
might not have favored the use ofthe con-
scious dog, the article clearly supports the
notion thathe held atthattime and thathas
continued to merit study.
Dr. Peters introduced the intravenous
glucose tolerance test, which is still used
today to diagnose diabetes and in fact is
used in a variety of other ways now to
measure degrees of insulin resistance, to
measure insulin secretion, and anumberof
other factors.
Dr. Peters used avery careful quantita-
tive methodology. While he didn't believe
patients should be statistics, he did believe
that science should be statistically proven.
He had clear views about both the
application ofscience and the management
of patients with diabetes: "The common
practice of speaking of spontaneous dia-
betes mellitus of man as a disease, is not
yet, and may never be, justified. The term
is applied to any condition in which the
oxidation of carbohydrate is chronically
impaired." It is a concept that we continue
to struggle with today. We have at least
made some progress in dividing diabetes
into Type 1, a clear autoimmune disease,
and Type 2, a disease of insulin resistance
butundoubtedly adisease made up ofmul-
tiple different etiologic categories. Dr.
Peters understood this at a very early time.
Peters noted, "Diabetes is one of the
most common disorders, the incidence in
the population is as high as 10 percent."
That's very close to the statistics that we
actually use today. He then goes on to
point out the nightmare ofdetermining the
genetics of the disease, something we
clearly do not understand even now,
although we've made progress in our
understanding. We can define autosomal
dominant forms of diabetes known asGorden: Remarks 15
MODY diabetes. We can define syn-
dromes of defective insulin receptors. We
can find mitochondrial disorders in which
the genetic disease is actually known. We
can at least have a very early glimpse of
the etiologic classifications of diabetes,
something that Dr. Peters was greatly con-
cerned about.
He also pointed out, "So great is the
incidence of vascular disease that it is
regarded by many as aconsequence ofdia-
betes. It is, however, a fallacy to presume
that because two variables are correlated
with one another they have the relation of
cause and effect, or without other grounds
to assign to one ofthem the role ofcause."
That could perhaps relate to many things,
but it clearly relates to our understanding
of macro-vascular disease. While we do
not understand why that disease is so
accelerated in diabetes, we can at least
strip away the micro-vascular classifica-
tion today and clearly attribute that to the
metabolic disorder that is associated with
diabetes. So, Dr. Peters would perhaps be
pleased to know that at least a subset of
this particular dilemma that concerned
him can be answered today.
He stated, "On the other hand, some
patients with clinical diabetes often
require far larger doses of insulin to con-
trol glycousuria and hyperglycemia and
can be withdrawn from insulin without a
dramatic reaction." How could one
describe what we call Type 2 diabetes any
better today?
Peters wrote, "Since all of the activi-
ties and vicissitudes of life influence the
course of diabetes, no satisfactory thera-
peutic regimen can be established or
adjusted in a hospital. Hospitalization is
necessary or desirable only for the man-
agement of complicating conditions or
emergencies." Clearly Dr. Peters under-
stood that diabetes is a disease in which
the patient must participate, and that the
interaction between the doctor and the
patient can influence the disease.
The objective in the treatment of any
chronic disease should be to enable the
patient to enjoy as full and active a life as
possible, according to Dr. Peters.
"Medicine should not be entirely negative
and restrictive. It should especially avoid
emptying life of the features that give
enjoyment and a sense of accomplish-
ment." This is a very sensitive statement
about the practice of medicine. "It is too
early to congratulate ourselves and some-
what ridiculous to blame patients for the
incidence of these associated, complicat-
ing conditions. Some ofthe most medical-
ly virtuous have succumbed early while
rascals have escaped," he went on. "I
would not say that only the good die
young, but experience has convinced me
that in this as in many another panels of
life, virtue too often has to be its own and
only reward."
Diabetes has an enormous effect with
respect to kidney disease, amputations,
and many other aspects. Cardiovascular
disease is two times more common;
stroke, two- to four-fold more common;
and diabetes is the leading cause of new
cases ofblindness.
Now, what are we doing about this?
The Captopril Study demonstrates that the
administration ofCaptopril, an angiotensin
converting enzyme inhibitor will amelio-
rate the course of end-stage renal disease
by a factor of close to 50 percent at doses
that do not effect blood pressure [3].
The Diabetes Control and
Complication Trial, the largest clinical
study of diabetes ever undertaken, is a
study that has brought diabetes into the
realm of what we now know is so impor-
tant in cholesterol and hypertension con-
trol [4]. Because of this study, we can
ascribe the same benefits to glycemic con-
trol.
Figure 1 shows glycosylated hemoglo-
bin values on the vertical axis. There is a
control group and an intensely treated
group. There is only a20 percent difference16 Gorden: Remarks
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in their glycosylated hemoglobin levels,
andyetyou see thatalltheintensively treat-
ed patients are still abnormal as shown by
the shaded line. This study has proven that
we can interdict the course of retinopathy
by 27 to 76 percent, of nephropathy by 34
to 57 percent, and neuropathy by 60 per-
cent. It is this kind of study that permitted
me in my testimony to the Congress to
defend an NIH budget of $14.6 billion for
fiscal year 1999 and $944 million for my
own institute. Figure 2 shows what I was
able topresentto the Congress. The vertical
axis represents the percentage of the
patients with end-stage renal disease, and
the top line indicates what happens in the
natural state, that is, under no particular
therapy. The next line indicates what we
can do with tertiary prevention, that is, the
Captopril Trial. We can clearly reduce the
magnitude of that effect by a significant
amount. The next line shows what happens
in the diabetes control and complication
trial, with control of the metabolism and
blood sugar. Note how markedly end-stage
renal disease is reduced. The dashed line
indicates what happens in a primary pre-
vention trial. Now the first two are already
done, we have results. The only thing we
have to do there is to actually implement
this. The last line is theoretical, it is a study
that is ongoing, and the line is drawn to
simulate the outcome of the study. Should
we get a positive effect in the primary pre-
vention study, we could reduce the course
ofend-stage renal disease to almost zero.
And now on a more personal note, as
a full-time employee of the Federal
Government, I thinkit would notbe appro-
priate to simply reiterate or apologize for
our government's treatment of Dr. Peters.
However, I think what is important is to
see how he has thrown down the gauntlet
forus. From the government's perspective,
there is enormous support for biomedical
research, and the National Institutes of
Health is attempting to fully respond to the
challenge. To meet thechallenge presentedGorden: Remarks 17
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by Dr. Peters, we must do everything pos-
sible to create healthy behaviors, such as
smoking cessation. We must do everything
possible to transmit this enormous energy
of science into improving the health care
of all people. That, I believe, would be an
appropriate tribute to Dr. John Punnett
Peters.
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